Cysteine-Engineered FN3 Domains for Homogeneous Drug Conjugation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current small molecule and antibody-based approaches for inhibiting EGFR and c-Met signaling pathways in cancer therapy face issues with specificity and toxicity, and conventional antibody-drug conjugates are heterogeneous and difficult to manufacture due to challenges in conjugating cytotoxic drugs effectively.

Innovation Solution

Development of cysteine-engineered fibronectin type III (FN3) domain molecules with specific cysteine substitutions that can bind to EGFR and c-Met, allowing for homogeneous chemical conjugation of cytotoxic drugs, thereby enhancing anti-tumor activity while minimizing off-target effects.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If conventional antibody-drug conjugates are used, then cytotoxic drugs can be delivered to target cells, but the conjugates are heterogeneous and difficult to manufacture with consistent quality

Engineering Contradiction:

Improvehomogeneity of drug conjugationVSAvoiddifficulty in manufacturing consistent conjugates

Core Design Contradiction:

Manufacturing precisionVSEase of manufacture

Solution Approach 1:

The patent changes the chemical parameters of the antibody by introducing specific cysteine residues at defined positions, replacing conventional lysine-based conjugation. This enables site-specific drug attachment with controlled stoichiometry, producing homogeneous ADCs with consistent pharmacokinetic and pharmacodynamic properties while simplifying manufacturing quality control

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The invention applies local quality by introducing cysteine residues at specific local positions on the antibody molecule (e.g., Cys L232, Cys H239 in IgG1). This localized modification enables precise control over drug conjugation sites, ensuring uniform drug distribution and consistent therapeutic activity across all conjugate molecules

Inventive Principle:

Principle #3Local quality

2Object-affected harmful factors

If small molecule and antibody-based approaches are used to inhibit EGFR and c-Met signaling, then anti-tumor activity is achieved, but specificity is reduced leading to off-target effects and toxicity

Engineering Contradiction:

Improvetoxicity and off-target effectsVSAvoidspecificity of target inhibition

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent segments the therapeutic function by creating separate binding domains for EGFR and c-Met within a single molecular construct. The Fn3 domain specifically targets EGFR while the IgG domain provides c-Met binding, enabling selective inhibition of these two receptors simultaneously without affecting other pathways, thereby reducing off-target toxicity while maintaining reliable anti-tumor activity

Inventive Principle:

Principle #1Segmentation

Data Source

PatentUS10662235B2Cysteine engineered fibronectin type III domain binding molecules

Publication Date: 2020.05.26 JANSSEN BIOTECH INC

AI summary

Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.